China Biologics Market Size & Outlook, 2026-2033
Global Market
Related Markets
China biologics market highlights
- The China biologics market generated a revenue of USD 26,024.1 million in 2025 and is expected to reach USD 58,847.3 million by 2033.
- The China market is expected to grow at a CAGR of 10.6% from 2026 to 2033.
- In terms of segment, microbial was the largest revenue generating source in 2025.
- Mammalian is the most lucrative source segment registering the fastest growth during the forecast period.
Biologics market data book summary
| Market revenue in 2025 | USD 26,024.1 million |
| Market revenue in 2033 | USD 58,847.3 million |
| Growth rate | 10.6% (CAGR from 2026 to 2033) |
| Largest segment | Microbial |
| Fastest growing segment | Mammalian |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Microbial, Mammalian |
| Key market players worldwide | Samsung BioLogics, Amgen Inc, Novo Nordisk A/S ADR, AbbVie Inc, Sanofi SA, Johnson & Johnson, Celltrion Healthcare, Bristol-Myers Squibb Co, Eli Lilly and Co, Roche Holding AG ADR |
Other key industry trends
- In terms of revenue, China accounted for 4.2% of the global biologics market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, Japan biologics market is projected to lead the regional market in terms of revenue in 2033.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 51,059.6 million by 2033.
One of the key drivers responsible for the emergence of the Chinese biologic market is the continuous proliferation of biologic developing plants in the country. In the current scenario, China has received gradual recognition as a commercially attractive market for biologics sales.
Continuous efforts by the regulators, policymakers, and the pharmaceutical industry jointly to address both the affordability and availability of biologics, especially mAbs, are anticipated to expand the Chinese market size of biologics in the coming years.
In December 2015, AstraZeneca undertook several strategic initiatives for acceleration of innovative biologics and targeted medicines delivery to patients in China. Strategic initiatives included a partnership with WuXi AppTec for the production of innovative biologics and investment in building a manufacturing site in Wuxi City.
No credit card required*
Publish Date: Jun 11, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Biologics Market Scope
Biologics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| Roche Holding AG ADR | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Novo Nordisk A/S ADR | View profile | 66,015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | www.novonordisk.com |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.samsungbiologics.com/ |
| Celltrion Healthcare | View profile | 51-100 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.celltrionhealthcare.com/ |
China Biologics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biologics Market Outlook will help companies and investors design strategic landscapes.
Microbial was the largest segment with a revenue share of 64.91% in 2025.
Horizon Databook has segmented the China biologics market based on microbial, mammalian covering the revenue growth of each sub-segment from 2021 to 2033.
One of the key drivers responsible for the emergence of the Chinese biologic market is the continuous proliferation of biologic developing plants in the country. In the current scenario, China has received gradual recognition as a commercially attractive market for biologics sales.
Continuous efforts by the regulators, policymakers, and the pharmaceutical industry jointly to address both the affordability and availability of biologics, especially mAbs, are anticipated to expand the Chinese market size of biologics in the coming years.
In December 2015, AstraZeneca undertook several strategic initiatives for acceleration of innovative biologics and targeted medicines delivery to patients in China. Strategic initiatives included a partnership with WuXi AppTec for the production of innovative biologics and investment in building a manufacturing site in Wuxi City.
- China Biologics Market Source Outlook (Revenue, USD Million , 2021-2033)
- Microbial
- Mammalian
- Others
- China Biologics Market Product Outlook (Revenue, USD Million , 2021-2033)
- Monoclonal antibodies (MABs)
- Vaccines
- Recombinant Proteins
- Antisense & RNAi Therapeutics
- Others
- China Biologics Market Disease Category Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Infectious Diseases
- Immunological Disorders
- Cardiovascular Disorders
- Haematological Disorders
- Others
- China Biologics Market Manufacturing Outlook (Revenue, USD Million , 2021-2033)
- In-house
- Outsourced
Reasons to subscribe to Biologics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Biologics Market Outlook databook
- Our clientele includes a mix of Biologics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China Biologics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into China Biologics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
China Biologics Market, 2021-2033 (US$M)
China Source - Biologics Market Statistics, 2025 - 2033 (US$M)
Related industry reports
No Records
No related reports found.
Related statistics
No Records
No related statistics found.